Patent Applications, Patent Litigation, Amgen

Amgen and Accord BioPharma Settle Denosumab BPCIA Case

Goodwin on 7/24/2025

On July 16, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen, Inc. (“Amgen”) and Accord BioPharma, Inc. (“Accord”)...more

Broad Biotech Patent Claims-the Saga Continues

Lathrop GPM on 6/27/2024

There now is increased interest about the written description and enablement requirements for patent applications claiming antibodies. This may stem from the recent U.S. Supreme Court decision in Amgen v. Sanofi, finding lack...more

[Webinar] Is Your Life Sciences Patent Enabled? - March 14th, 12:00 pm PT

Procopio, Cory, Hargreaves & Savitch LLP on 2/23/2023

U.S. Supreme Court Will Decide This Year - In this year’s foray into patent law, the Supreme Court will decide whether Amgen’s patent that claims antibodies by functional antigen binding and does not disclose the full...more

When Time is Money

Robins Kaplan LLP on 12/27/2016

As the Biologics market is predicted to be a $250 billion market in the next few years, it is not surprising that parties embroiled in biosimilar litigation go to the mat. Both Apotex and Sandoz filed cert petitions this year...more

Enbrel Biosimilar Approved in US But Enjoined For Now

Patterson Belknap Webb & Tyler LLP on 9/1/2016

On August 30 FDA approved Sandoz Inc.’s biosimilar of Enbrel (etanercept), Amgen Inc.’s blockbuster biologic for treatment of moderate to severe rheumatoid arthritis and a number of other autoimmune conditions. The...more

"Don't Stop the Dance"[*] -- The Dissents-in-Part from Amgen v. Sandoz

McDonnell Boehnen Hulbert & Berghoff LLP on 7/24/2015

As we have been reporting this week, the Federal Circuit handed down its decision in Amgen Inc. v. Sandoz Inc. -- a case of first impression relating to the Biologics Price Competition and Innovation Act ("BPCIA") for...more